My research focuses on the downstream aspect of the drug discovery process. I am responsible for determining safety and pharmacological properties of novel compounds. I lead a small team of researchers that uses high-throughput screening and mass spectrometry to select safe, potent compounds for pre-clinical trials. We use various animal models to demonstrate therapeutic efficacy against a range of infectious diseases, drug-resistant cancers, and neurodegenerative diseases.